Core Insights - Aino Health experienced a 20% increase in revenue in Q2 2025 compared to Q2 2024, indicating a positive growth trajectory [2] - The company achieved a positive EBITDA, reflecting improved operational efficiency and the strength of its business model [2] - Strategic price adjustments were made in collaboration with customers, leading to some concluded customer relationships and a reduction in active licenses [2] Financial Performance - Total turnover for the first half of 2025 was 14,848 TSEK, up from 12,230 TSEK in the same period of the previous year [7] - Profit after financial items improved to -1,141 TSEK from -4,960 TSEK year-over-year [7] - Earnings per share remained stable at -0.0 SEK compared to -0.1 SEK in the previous year [7] Customer and Market Dynamics - The quarter saw increased momentum in new customer signings and platform rollouts, particularly in the manufacturing sector [3] - Aino Health's focus on industries with high complexity and large workforces has proven successful as organizations prioritize data-driven work ability management [3] - The onboarding of large customers is progressing as planned, contributing to a strengthening recurring revenue base [4] Future Outlook - The company is committed to driving long-term value through innovation, customer success, and measurable health outcomes [5] - Aino Health anticipates continued profitable growth in 2025, supported by a solid pipeline and expanding market demand [5]